Exercise protects against MPTP-induced neurotoxicity in mice

Brain Research

Volumn 1341, Issue , 2010, Pages 72-83

  Gerecke, Kimberly M ^a,b   Jiao, Yun ^b   Pani, Amar ^b   Pagala, Vishwajeeth ^b   Smeyne, Richard J ^b  

^a RHODES COLLEGE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Exercise; MPTP; Parkinson's disease; Proteomics; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HOMOVANILLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL METABOLISM; CONTROLLED STUDY; CORPUS STRIATUM; CYTOSKELETON; DOPAMINERGIC NERVE CELL; ENERGY BALANCE; FEMALE; INTRACELLULAR SIGNALING; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEOMICS; SUBSTANTIA NIGRA; TREADMILL EXERCISE; TREATMENT DURATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CYTOPROTECTION; DISEASE MODELS, ANIMAL; FEMALE; MALE; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEURONS; NEUROTOXINS; PARKINSONIAN DISORDERS; PHYSICAL CONDITIONING, ANIMAL; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

MUS;

EID: 77953104126     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.01.053     Document Type: Article

References (111)

1. Anantharam V., Kaul S., Song C., Kanthasamy A., and Kanthasamy A.G. Pharmacological inhibition of neuronal NADPH oxidase protects against 1-methyl-4-phenylpyridinium (MPP+)-induced oxidative stress and apoptosis in mesencephalic dopaminergic neuronal cells. Neurotoxicology 28 (2007) 988-997
2. Andreeva A.V., Kutuzov M.A., and Voyno-Yasenetskaya T.A. A ubiquitous membrane fusion protein alpha SNAP: a potential therapeutic target for cancer diabetes and neurological disorders?. Expert Opin. Ther. Targets 10 (2006) 723-733
3. Anstrom K.K., Schallert T., Woodlee M.T., Shattuck A., and Roberts D.C. Repetitive vibrissae-elicited forelimb placing before and immediately after unilateral 6-hydroxydopamine improves outcome in a model of Parkinson's disease. Behav. Brain Res. 179 (2007) 183-191
4. Baquet Z.C., Williams D., Brody J., and Smeyne R.J. A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouse. Neuroscience 161 (2009) 1082-1090
5. Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., Jaros E., Hersheson J.S., Betts J., Klopstock T., Taylor R.W., and Turnbull D.M. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 38 (2006) 515-517
6. Bizzoco E., Faussone-Pellegrini M.S., and Vannucchi M.G. Activated microglia cells express argininosuccinate synthetase and argininosuccinate lyase in the rat brain after transient ischemia. Exp. Neurol. 208 (2007) 100-109
7. Bloomer R.J., Schilling B.K., Karlage R.E., Ledoux M.S., Pfeiffer R.F., and Callegari J. Effect of resistance training on blood oxidative stress in Parkinson disease. Med. Sci. Sports Exerc. 40 (2008) 1385-1389
8. Boyd J.D., Jang H., Shepherd K.R., Faherty C., Slack S., Jiao Y., and Smeyne R.J. Response to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta. Brain Res. 1175 (2007) 107-116
9. Brooks W.J., Jarvis M.F., and Wagner G.C. Astrocytes as a primary locus for the conversion MPTP into MPP+. J. Neural. Transm. 76 (1989) 1-12
10. Bueler H. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp. Neurol. 218 (2009) 235-246
11. Cechetti F., Fochesatto C., Scopel D., Nardin P., Goncalves C.A., Netto C.A., and Siqueira I.R. Effect of a neuroprotective exercise protocol on oxidative state and BDNF levels in the rat hippocampus. Brain Res. 1188 (2008) 182-188
12. Chen M.J., and Russo-Neustadt A.A. Running exercise-induced up-regulation of hippocampal brain-derived neurotrophic factor is CREB-dependent. Hippocampus (2009)
13. Chen H., Zhang S.M., Schwarzschild M.A., Hernan M.A., and Ascherio A. Physical activity and the risk of Parkinson disease. Neurology 64 (2005) 664-669
14. Chmurzynska A. The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet. 47 (2006) 39-48
15. Chodzko-Zajko W.J., and Moore K.A. Physical fitness and cognitive functioning in aging. Exerc. Sport Sci. Rev. 22 (1994) 195-220
16. Chytrova G., Ying Z., and Gomez-Pinilla F. Exercise normalizes levels of MAG and Nogo-A growth inhibitors after brain trauma. Eur. J. NeuroSci. 27 (2008) 1-11
17. Clarke S. Aging as war between chemical and biochemical processes: protein methylation and the recognition of age-damaged proteins for repair. Ageing Res. Rev. 2 (2003) 263-285
18. Cohen A.D., Tillerson J.L., Smith A.D., Schallert T., and Zigmond M.J. Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF. J. Neurochem. 85 (2003) 299-305
19. Colcombe S.J., Erickson K.I., Raz N., Webb A.G., Cohen N.J., McAuley E., and Kramer A.F. Aerobic fitness reduces brain tissue loss in aging humans. J Gerontol A Biol Sci Med Sci. 58 (2003) 176-180
20. Colcombe S.J., Kramer A.F., Erickson K.I., Scalf P., McAuley E., Cohen N.J., Webb A., Jerome G.J., Marquez D.X., and Elavsky S. Cardiovascular fitness, cortical plasticity, and aging. Proc Natl Acad Sci U S A. 101 (2004) 3316-3321
21. Cooper J.R., Bloom F.E., and Roth R.H. The Biochemical Basis of Neuropharmacology (2002), Oxford University Press, New York, Vol.
22. Cotman C.W., and Berchtold N.C. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 25 (2002) 295-301
23. Croft B.G., Fortin G.D., Corera A.T., Edwards R.H., Beaudet A., Trudeau L.E., and Fon E.A. Normal biogenesis and cycling of empty synaptic vesicles in dopamine neurons of vesicular monoamine transporter 2 knockout mice. Mol. Biol. Cell 16 (2005) 306-315
24. Cui M., Aras R., Christian W.V., Rappold P.M., Hatwar M., Panza J., Jackson-Lewis V., Javitch J.A., Ballatori N., Przedborski S., and Tieu K. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A. 106 (2009) 8043-8048
25. Del Zompo M., Piccardi M.P., Ruiu S., Quartu M., Gessa G.L., and Vaccari A. Selective MPP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity. Br. J. Pharmacol. 109 (1993) 411-414
26. Ding Q., Vaynman S., Souda P., Whitelegge J.P., and Gomez-Pinilla F. Exercise affects energy metabolism and neural plasticity-related proteins in the hippocampus as revealed by proteomic analysis. Eur. J. NeuroSci. 24 (2006) 1265-1276
27. Emery C.F., Schein R.L., Hauck E.R., and MacIntyre N.R. Psychological and cognitive outcomes of a randomized trial of exercise among patients with chronic obstructive pulmonary disease. Health Psychol. 17 (1998) 232-240
28. Faherty C.J., Raviie Shepherd K., Herasimtschuk A., and Smeyne R.J. Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism. Brain Res. Mol. Brain Res. 134 (2005) 170-179
29. Fahn S. Is levodopa toxic?. Neurology 47 (1996) S184-S195
30. Feng L., Hatten M.E., and Heintz N. Brain lipid-binding protein (BLBP): a novel signaling system in the developing mammalian CNS. Neuron 12 (1994) 895-908
31. Fisher B.E., Petzinger G.M., Nixon K., Hogg E., Bremmer S., Meshul C.K., and Jakowec M.W. Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned mouse basal ganglia. J Neurosci Res. 77 (2004) 378-390
32. Fornai F., Battaglia G., Gesi M., Giorgi F.S., Orzi F., Nicoletti F., and Ruggieri S. Time-course and dose-response study on the effects of chronic L-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity. Brain Res. 887 (2000) 110-117
33. Gainetdinov R.R., Fumagalli F., Jones S.R., and Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69 (1997) 1322-1325
34. Gainetdinov R.R., Fumagalli F., Wang Y.M., Jones S.R., Levey A.I., Miller G.W., and Caron M.G. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J. Neurochem. 70 (1998) 1973-1978
35. Galea C.A., Pagala V.R., Obenauer J.C., Park C.G., Slaughter C.A., and Kriwacki R.W. Proteomic studies of the intrinsically unstructured mammalian proteome. J Proteome Res. 5 (2006) 2839-2848
36. Gao H.M., Liu B., Zhang W., and Hong J.S. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J. 17 (2003) 1954-1956
37. Garcia O., Almeida A., Massieu L., and Bolanos J.P. Increased mitochondrial respiration maintains the mitochondrial membrane potential and promotes survival of cerebellar neurons in an endogenous model of glutamate receptor activation. J. Neurochem. 92 (2005) 183-190
38. German D.C., Manaye K., Smith W.K., Woodward D.J., and Saper C.B. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann. Neurol. 26 (1989) 507-514
39. Griesbach G.S., Hovda D.A., and Gomez-Pinilla F. Exercise-induced improvement in cognitive performance after traumatic brain injury in rats is dependent on BDNF activation. Brain Res. 1288 (2009) 105-115
40. Guezennec C.Y., Abdelmalki A., Serrurier B., Merino D., Bigard X., Berthelot M., Pierard C., and Peres M. Effects of prolonged exercise on brain ammonia and amino acids. Int. J. Sports Med. 19 (1998) 323-327
41. Hamre K., Tharp R., Poon K., Xiong X., and Smeyne R.J. Differential strain susceptibility following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res. 828 (1999) 91-103
42. Hawkins H.L., Kramer A.F., and Capaldi D. Aging, exercise, and attention. Psychol. Aging 7 (1992) 643-653
43. Hornykiewicz O. Mechanisms of neuronal loss in Parkinson's disease: a neuroanatomical-biochemical perspective. Clin. Neurol. Neurosurg. 94 (1992) S9-S11 Suppl
44. Jackson-Lewis V., Jakowec M., Burke R.E., and Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Neurodegeneration 4 (1995) 257-269
45. Jankovic J., and Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs. 21 (2007) 677-692
46. Janssen U., Davis E.M., Le Beau M.M., and Stoffel W. Human mitochondrial enoyl-CoA hydratase gene (ECHS1): structural organization and assignment to chromosome 10q26.2-q26.3. Genomics 40 (1997) 470-475
47. Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol. Scand. Suppl. 136 (1991) 6-15
48. Kawahara K., Gotoh T., Oyadomari S., Kajizono M., Kuniyasu A., Ohsawa K., Imai Y., Kohsaka S., Nakayama H., and Mori M. Co-induction of argininosuccinate synthetase, cationic amino acid transporter-2, and nitric oxide synthase in activated murine microglial cells. Brain Res. Mol. Brain Res. 90 (2001) 165-173
49. Kopin I.J. Features of the dopaminergic neurotoxin MPTP. Ann. N. Y. Acad. Sci. 648 (1992) 96-104
50. Korell M., and Tanner C.M. In: Ebadi M., and Pfeiffer R.F. (Eds). Epidemiology of Parkinson's Disease. An Overview (2004), CRC Press, Boca Raton 39-50 Vol.
51. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chromic parkinsonism in humans due to a product of merperidine-analog synthesis. Science 219 (1983) 979-980
52. Lautenschlager N.T., Cox K.L., Flicker L., Foster J.K., van Bockxmeer F.M., Xiao J., Greenop K.R., and Almeida O.P. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 300 (2008) 1027-1037
53. Lemaster J.J., and Thurman R.G. Hypoxia and reperfusion injury to liver. Prog. Liver Dis. 11 (1993) 85-114
54. Levine R.A., Kapatos G., Kaufman S., and Milstien S. Immunological evidence for the requirement of sepiapterin reductase for tetrahydrobiopterin biosynthesis in brain. J. Neurochem. 54 (1990) 1218-1224
55. Mabandla M., Kellaway L., St Clair Gibson A., and Russell V.A. Voluntary running provides neuroprotection in rats after 6-hydroxydopamine injection into the medial forebrain bundle. Metab. Brain Dis. 19 (2004) 43-50
56. Mandel S., Grunblatt E., Riederer P., Gerlach M., Levites Y., and Youdim M.B. Neuroprotective strategies in Parkinson's disease : an update on progress. CNS Drugs 17 (2003) 729-762
57. Mattson M.P. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann. N. Y. Acad. Sci. 1144 (2008) 97-112
58. McGeer P.L., and McGeer E.G. Glial reactions in Parkinson's disease. Mov. Disord. 23 (2008) 474-483
59. Miller G.W., Gainetdinov R.R., Levey A.I., and Caron M.G. Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 20 (1999) 424-429
60. Muenter M.D., and Tyce G.M. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin. Proc. 46 (1971) 231-239
61. Mursula, A., 2002. Δ3-Δ2-Enoyl-CoA isomerase from the yeast Saccharomyces cerevisiae.
62. Muthane U., Ramsay K.A., Jiang H., Jackson-Lewis V., Donaldson D., Fernando S., Ferreira M., and Przedborski S. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in C57/bl and CD-1 mice. Exp. Neurol. 126 (1994) 195-204
63. Nagi M.N., Cook L., Laguna J.C., and Cinti D.L. Dual action of 2-decynoyl coenzyme A: inhibitor of hepatic mitochondrial trans-2-enoyl coenzyme A reductase and peroxisomal bifunctional protein and substrate for the mitochondrial beta-oxidation system. Arch. Biochem. Biophys. 267 (1988) 1-12
64. Neeper S.A., Gomez-Pinilla F., Choi J., and Cotman C. Exercise and brain neurotrophins. Nature 373 (1995) 109
65. Nishi K., Kondo T., and Narabayashi H. Difference in recovery patterns of striatal dopamine content, tyrosine hydroxylase activity and total biopterin content after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) administration: a comparison of young and older mice. Brain Res. 489 (1989) 157-162
66. Obata T. Dopamine efflux by MPTP and hydroxyl radical generation. J. Neural. Transm. Suppl. 109 (2002) 1159-1180
67. O'Callaghan D.W., Tepikin A.V., and Burgoyne R.D. Dynamics and calcium sensitivity of the Ca2+/myristoyl switch protein hippocalcin in living cells. J Cell Biol. 163 (2003) 715-721
68. O'Callaghan R.M., Griffin E.W., and Kelly A.M. Long-term treadmill exposure protects against age-related neurodegenerative change in the rat hippocampus. Hippocampus 19 (2009) 1019-1029
69. O'Dell S.J., Gross N.B., Fricks A.N., Casiano B.D., Nguyen T.B., and Marshall J.F. Running wheel exercise enhances recovery from nigrostriatal dopamine injury without inducing neuroprotection. Neuroscience. 144 (2007) 1141-1151
70. Olanow C.W. Oxidation reactions in Parkinson's disease. Neurology 40 Suppl.3 (1990) 32-37
71. Olanow C.W., and Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Ann. Rev. Neurosci. 22 (1999) 123-144
72. Petzinger G.M., Walsh J.P., Akopian G., Hogg E., Abernathy A., Arevalo P., Turnquist P., Vuckovic M., Fisher B.E., Togasaki D.M., and Jakowec M.W. Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J. Neurosci. 27 (2007) 5291-5300
73. Ploughman M., Windle V., MacLellan C.L., White N., Dore J.J., and Corbett D. Brain-derived neurotrophic factor contributes to recovery of skilled reaching after focal ischemia in rats. Stroke 40 (2009) 1490-1495
74. Pothakos K., Kurz M.J., and Lau Y.S. Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration. BMC Neurosci. 10 (2009) 6
75. Poulton N.P., and Muir G.D. Treadmill training ameliorates dopamine loss but not behavioral deficits in hemi-parkinsonian rats. Exp. Neurol. 193 (2005) 181-197
76. Przedborski S., and Vila M. The last decade in Parkinson's disease research. Basic sciences. Adv. Neurol. 86 (2001) 177-186
77. Qin W., Khuchua Z., Cheng J., Boero J., Payne R.M., and Strauss A.W. Molecular characterization of the creatine kinases and some historical perspectives. Mol. Cell. Biochem. 184 (1998) 153-167
78. Radak Z., Kumagai S., Taylor A.W., Naito H., and Goto S. Effects of exercise on brain function: role of free radicals. Appl. Physiol. Nutr. Metab. 32 (2007) 942-946
79. Ransom B.R., Kunis D.M., Irwin I., and Langston J.W. Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+. Neurosci. Lett. 75 (1987) 323-328
80. Rasmussen P., Brassard P., Adser H., Pedersen M.V., Leick L., Hart E., Secher N.H., Pedersen B.K., and Pilegaard H. Evidence for a release of BDNF from the brain during exercise. Exp. Physiol. 94 (2009) 1062-1069
81. Reshef L., Olswang Y., Cassuto H., Blum B., Croniger C.M., Kalhan S.C., Tilghman S.M., and Hanson R.W. Glyceroneogenesis and the triglyceride/fatty acid cycle. J Biol Chem. 278 (2003) 30413-30416
82. Sandri M., Podhorska-Okolow M., Geromel V., Rizzi C., Arslan P., Franceschi C., and Carraro U. Exercise induces myonuclear ubiquitination and apoptosis in dystrophin-deficient muscle of mice. J .Neuropathol. Exp. Neurol. 56 (1997) 45-57
83. Sandrow-Feinberg H.R., Izzi J., Shumsky J.S., Zhukareva V., and Houle J.D. Forced exercise as a rehabilitation strategy after unilateral cervical spinal cord contusion injury. J. Neurotrauma. 26 (2009) 721-731
84. Scacco S., Vergari R., Scarpulla R.C., Technikova-Dobrova Z., Sardanelli A., Lambo R., Lorusso V., and Papa S. cAMP-dependent phosphorylation of the nuclear encoded 18-kDa (IP) subunit of respiratory complex I and activation of the complex in serum-starved mouse fibroblast cultures. J. Biol. Chem. 275 (2000) 17578-17582
85. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54 (1990) 823-827
86. Scorziello A., Santillo M., Adornetto A., Dell'aversano C., Sirabella R., Damiano S., Canzoniero L.M., Renzo G.F., and Annunziato L. NO-induced neuroprotection in ischemic preconditioning stimulates mitochondrial Mn-SOD activity and expression via Ras/ERK1/2 pathway. J. Neurochem. 103 (2007) 1472-1480
87. Sedelis M., Hofele K., Auburger G.W., Morgan S., Huston J.P., and Schwarting R.K. Evidence for resistance to MPTP in C57BL/6 × BALB/c F1 hybrids as compared with their progenitor strains. NeuroReport 11 (2000) 1093-1096
88. Siamilis S., Jakus J., Nyakas C., Costa A., Mihalik B., Falus A., and Radak Z. The effect of exercise and oxidant-antioxidant intervention on the levels of neurotrophins and free radicals in spinal cord of rats. Spinal Cord. 47 (2009) 453-457
89. Smeyne R.J., and Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res. Mol. Brain Res. 134 (2005) 57-66
90. Smith A.D., and Zigmond M.J. Can the brain be protected through exercise? Lessons from an animal model of parkinsonism. Exp. Neurol. 184 (2003) 31-39
91. Steiner B., Winter C., Hosman K., Siebert E., Kempermann G., Petrus D.S., and Kupsch A. Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson's disease. Exp. Neurol. 199 (2006) 291-300
92. Swerdlow R.H., Parks J.K., Davis II J.N., Cassarino D.S., Trimmer P.A., Currie L.J., Dougherty J., Bridges W.S., Bennett Jr. J.P., Wooten G.F., and Parker W.D. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann. Neurol. 44 (1998) 873-881
93. Tatton W.G., Greenwood C.E., Seniuk N.A., and Salo P.T. Interactions between MPTP-induced and age-related neuronal death in a murine model of Parkinson's disease. Can. J. Neurol. Sci. 19 (1992) 124-133
94. Teismann P., Tieu K., Cohen O., Choi D.K., Wu D.C., Marks D., Vila M., Jackson-Lewis V., and Przedborski S. Pathogenic role of glial cells in Parkinson's disease. Mov. Disord. 18 (2003) 121-129
95. Terzioglu M., and Galter D. Parkinson's disease: genetic versus toxin-induced rodent models. FEBS J. 275 (2008) 1384-1391
96. Tillerson J.L., Caudle W.M., Reveron M.E., and Miller G.W. Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease. Neuroscience. 119 (2003) 899-911
97. Um H.S., Kang E.B., Leem Y.H., Cho I.H., Yang C.H., Chae K.R., Hwang D.Y., and Cho J.Y. Exercise training acts as a therapeutic strategy for reduction of the pathogenic phenotypes for Alzheimer's disease in an NSE/APPsw-transgenic model. Int. J. Mol. Med. 22 (2008) 529-539
98. Van der Kloot W. Loading and recycling of synaptic vesicles in the Torpedo electric organ and the vertebrate neuromuscular junction. Prog. Neurobiol. 71 (2003) 269-303
99. Villar-Palasi C., and Larner J. Glycogen metabolism and glycolytic enzymes. Annu. Rev. Biochem. 39 (1970) 639-672
100. von Deimling O.H., Gaa A., and Simon M.M. Esterase-18 (ES-18) of the house mouse (Mus musculus): biochemical characterization and genetics of an allozyme system linked to chromosome 19. Biochem. Genet. 26 (1988) 617-629
101. Wang C.H., Lee W.J., Ghanta V.K., Wang W.T., Cheng S.Y., and Hsueh C.M. Molecules involve in the self-protection of neurons against glucose-oxygen-serum deprivation (GOSD)-induced cell damage. Brain Res. Bull. 79 (2009) 169-176
102. Willis D., Li K.W., Zheng J.Q., Chang J.H., Smit A., Kelly T., Merianda T.T., Sylvester J., van Minnen J., and Twiss J.L. Differential transport and local translation of cytoskeletal, injury-response, and neurodegeneration protein mRNAs in axons. J. Neurosci. 25 (2005) 778-791
103. Win H.K., Chang S.M., Raizner M., Shah G., Al Basky F., Desai U., Plana J.C., Mahmarian J.J., Quinones M.A., and Zoghbi W.A. Percent change in B-type natriuretic peptide levels during treadmill exercise as a screening test for exercise-induced myocardial ischemia. Am. Heart J. 150 (2005) 695-700
104. Witke W., Podtelejnikov A.V., Di Nardo A., Sutherland J.D., Gurniak C.B., Dotti C., and Mann M. In mouse brain profilin I and profilin II associate with regulators of the endocytic pathway and actin assembly. Embo. J. 17 (1998) 967-976
105. Yokoyama H., Kuroiwa H., Yano R., and Araki T. Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurol Sci. 29 (2008) 293-301
106. Yu X., Shao X.G., Sun H., Li Y.N., Yang J., Deng Y.C., and Huang Y.G. Activation of cerebral peroxisome proliferator-activated receptors gamma exerts neuroprotection by inhibiting oxidative stress following pilocarpine-induced status epilepticus. Brain Res. 1200 (2008) 146-158
107. Zang L.Y., and Misra H.P. Generation of reactive oxygen species during the monoamine oxidase catalyzed oxidation of the neurotoxicant, 1-methyl-4-phenyl-1, 2, 3, 6-tetra hydropyridine. J. Biol. Chem. 268 (1993) 16504-16512
108. Zappia M., Oliveri R.L., Montesanti R., Rizzo M., Bosco D., Plastino M., Crescibene L., Bastone L., Aguglia U., Gambardella A., and Quattrone A. Loss of long-duration response to levodopa over time in PD: implications for wearing-off. Neurology 52 (1999) 763-767
109. Zhang W.Y., Gotoh T., Oyadomari S., and Mori M. Coinduction of inducible nitric oxide synthase and arginine recycling enzymes in cytokine-stimulated PC12 cells and high output production of nitric oxide. Mol. Brain Res. 83 (2000) 1-8
110. Zhao X., Strong R., Zhang J., Sun G., Tsien J.Z., Cui Z., Grotta J.C., and Aronowski J. Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia. J. Neurosci. 29 (2009) 6186-6195
111. Zhu J.X., Doyle H.A., Mamula M.J., and Aswad D.W. Protein repair in the brain, proteomic analysis of endogenous substrates for protein l-isoaspartyl methyltransferase in mouse brain. J Biol Chem. 281 (2006) 33802-33813